Literature DB >> 9554334

Nephron sparing surgery for renal cell carcinoma 4 cm. or less in diameter: indicated or under treated?

H Wunderlich1, O Reichelt, S Schumann, A Schlichter, H Kosmehl, W Werner, R Vollandt, J Schubert.   

Abstract

PURPOSE: Although radical nephrectomy is the standard treatment for localized unilateral renal cell carcinoma with a normal contralateral kidney, there is ongoing interest in the use of nephron sparing surgery or partial nephrectomy in such cases. The extent of radical surgery in such cases has also been reconsidered in view of the uncertainty regarding the malignant or benign nature.
MATERIALS AND METHODS: Of 14,793 autopsies in Jena from 1985 until 1995 there were 260 renal cell carcinomas. Of the 260 renal cell carcinomas the diameter was 40 mm. or less in 104. These 104 tumors were divided into group 1-20 mm. or less (33 cases), group 2-21 to 30 mm. (28) and group 3-31 to 40 mm. (43).
RESULTS: Grade 1 renal cell carcinomas decreased in frequency with increasing tumor diameter, while an opposite result was noted for grade 3. Lymph node and distant metastases were well correlated with tumor size. With an increase in tumor size the frequency of venous involvement increased as well. Significantly more multifocal malignant renal cell carcinomas were seen in tumors between 21 and 40 mm. compared to those 20 mm. or less in diameter.
CONCLUSIONS: The metastatic potential and biology of these small nodules are not yet known. To lower the risk of local recurrence the results of our study suggest that nephron sparing surgery might be advisable in patients with renal cell carcinoma 20 mm. or less in diameter.

Entities:  

Mesh:

Year:  1998        PMID: 9554334     DOI: 10.1097/00005392-199805000-00012

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  MR Imaging of papillary renal neoplasms: potential application for characterization of small renal masses.

Authors:  Catherine Roy; Benoit Sauer; Véronique Lindner; Hervé Lang; Christian Saussine; Didier Jacqmin
Journal:  Eur Radiol       Date:  2006-06-07       Impact factor: 5.315

Review 2.  [Intraoperative frozen section diagnosis of the genitourinary tract].

Authors:  S Bertz; B J Schmitz-Dräger; C Protzel; A Hartmann
Journal:  Pathologe       Date:  2012-09       Impact factor: 1.011

3.  Characteristics of aggressive variants in T1a renal cell carcinoma.

Authors:  Tatsuya Takayama; Takayuki Sugiyama; Fumitake Kai; Takahisa Suzuki; Masahiro Nagata; Takeshi Imanishi; Takuji Mizuno; Shigenori Sato; Hiroshi Furuse; Soichi Mugiya; Seiichiro Ozono
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-28       Impact factor: 4.553

Review 4.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

5.  Metastatic renal cell carcinoma risk according to tumor size.

Authors:  R Houston Thompson; Jennifer R Hill; Yuriy Babayev; Angel Cronin; Matt Kaag; Shilajit Kundu; Melanie Bernstein; Jonathan Coleman; Guido Dalbagni; Karim Touijer; Paul Russo
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

6.  Risk of metastasis for T1a renal cell carcinoma.

Authors:  Hakmin Lee; Jung Keun Lee; Kwangmo Kim; Cheol Kwak; Hyeon Hoe Kim; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  World J Urol       Date:  2015-08-06       Impact factor: 4.226

7.  Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology.

Authors:  Pal Bata; Adam Domonkos Tarnoki; David Laszlo Tarnoki; Attila Marcell Szasz; Gergely Poloskei; Bence Fejer; Janos Gyebnar; Peter Nyirady; Viktor Berczi; Kinga Karlinger; Attila Szendroi
Journal:  J Res Med Sci       Date:  2014-07       Impact factor: 1.852

8.  Histological characterisation of small renal masses and incidence of silent renal masses.

Authors:  Sergio Almenar Medina; Ana Calatrava Fons
Journal:  Adv Urol       Date:  2008-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.